CEL-SCI Corp (CVM)
AMEXHealth CareBiotechnologySnapshot 2026-11-05
$1.37-0.72%
Close 2026-11-05 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · CVM
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers · Company calendar date is not available
CVM — debt issuance
Dated 2026-06-16
Entry into a Material Definitive Agreement. On June 14, 2026, CEL-SCI Corporation, a Colorado corporation (the “Company”), entered into a Placement Agency Agreement with ThinkEquity LLC (the “Placement Agent”) relating to the sale and issuance of 2,500,000 shares of the Company’s common stock, at an offering price of $1.00 per share (the “Shares”). The Offering closed on June 16, 2026. The gross proceeds from the Offering were $2,500,000 before deducting Placement Agent fees and offering expe…
Why it matters: Losses and cash use have stayed high across eight quarters. A clear drop could ease pressure to raise more money.
Supportive ifA quarterly report shows net loss below $5.5M and cash used in operations below $3.9M.
Worry ifA quarterly report shows net loss at or above $5.5M and cash used in operations at or above $3.9M.
Why it matters: The current agreement covers Saudi Arabia. A signed expansion could open more markets, though each would still need local approval.
Supportive ifCEL-SCI and Amarox announce a signed deal that adds one or more GCC countries beyond Saudi Arabia.
Worry ifCEL-SCI reports that the GCC option expired or that the partners ended talks about expansion.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$283 on $10,000 · ±2.8% | How much price usually moves either way. |
| Bad day | $1,120 loss on $10,000 · 11.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,730 loss on $10,000 · 87.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.